Implementing novel regimens for drug-resistant TB in South Africa : what can the world learn?

dc.contributor.authorNdjeka, N.en_ZA
dc.contributor.authorHughes, J.en_ZA
dc.contributor.authorReuter, A.en_ZA
dc.contributor.authorConradie, F.en_ZA
dc.contributor.authorEnwerem, M.en_ZA
dc.contributor.authorFerreira, H.en_ZA
dc.contributor.authorIsmail, N.en_ZA
dc.contributor.authorKock, Y.en_ZA
dc.contributor.authorMaster, I.en_ZA
dc.contributor.authorMeintjes, G.en_ZA
dc.contributor.authorPadanilam, X.en_ZA
dc.contributor.authorRomero, R.en_ZA
dc.contributor.authorSchaaf, H. S.en_ZA
dc.contributor.authorte Riele, J.en_ZA
dc.contributor.authorMaartens, G.en_ZA
dc.date.accessioned2022-09-22T09:17:43Zen_ZA
dc.date.available2022-09-22T09:17:43Zen_ZA
dc.date.issued2020-10en_ZA
dc.descriptionCITATION: Ndjeka, N. et al. 2020. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 24(10):1073–1080. doi:10.5588/ijtld.20.0174en_ZA
dc.descriptionThe original publication is available at https://www.ingentaconnect.com/content/iuatld/ijtlden_ZA
dc.description.abstractWorldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for the management of RR-TB, South Africa announced that bedaquiline (BDQ) would be provided to virtually all RR-TB patients on shorter or longer regimens. South Africa has been the global leader in accessing BDQ for patients with RR-TB, who now represent 60% of the global BDQ cohort. The use of BDQ within a shorter modified regimen has generated the programmatic data underpinning the most recent change in WHO guidelines endorsing a shorter, injectable-free regimen. Progressive policies on access to new drugs have resulted in improved favourable outcomes and a reduction in mortality among RR-TB patients in South Africa. This supported global policy change. The strategies underpinning these bold actions include close collaboration between the South African National TB Programme and partners, introduction of new TB diagnostic tools in closely monitored conditions and the use of locally generated programmatic evidence to inform country policy changes. In this paper, we summarise a decade´s work that led to the bold decision to use a modified, short, injectable-free regimen with BDQ and linezolid under carefully monitored programmatic conditions.en_ZA
dc.description.urihttps://www.ingentaconnect.com/content/iuatld/ijtld/2020/00000024/00000010/art00016en_ZA
dc.description.versionPublishers versionen_ZA
dc.format.extent9 pagesen_ZA
dc.identifier.citationNdjeka, N. et al. 2020. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 24(10):1073–1080. doi:10.5588/ijtld.20.0174en_ZA
dc.identifier.issn1815-7920 (online)en_ZA
dc.identifier.issn1027-3719 (print)en_ZA
dc.identifier.otherdoi:10.5588/ijtld.20.0174en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/125743en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen_ZA
dc.rights.holderThe Unionen_ZA
dc.subjectMultidrug-resistant tuberculosisen_ZA
dc.subjectDrug resistance -- South Africaen_ZA
dc.subjectTuberculosis -- Treatmenten_ZA
dc.subjectInjectable-free regimensen_ZA
dc.subjectShorter treatment regimenen_ZA
dc.titleImplementing novel regimens for drug-resistant TB in South Africa : what can the world learn?en_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ndjeka_implementing_2020.pdf
Size:
920.36 KB
Format:
Adobe Portable Document Format
Description:
Download article
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: